Trial Profile
An Open-label Extension to Study AVA105640, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) on Cognition in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms REFLECT-5
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 05 Jun 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
- 23 Mar 2011 Actual initiation date is Oct 2007 as reported by ClinicalTrials.gov (NCT00550420, Extention trial).
- 05 Nov 2010 New trial record.